Calcineurin inhibitor nephrotoxicity: A review and perspective of the evidence

American Journal of Nephrology

Volumn 37, Issue 6, 2013, Pages 602-612

  Issa, Naim ^a   Kukla, Aleksandra ^a   Ibrahim, Hassan N ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Calcineurin inhibitors; Chronic kidney disease; Graft loss; Kidney transplantation; Nephrotoxicity

Indexed keywords

ANTIFUNGAL AGENT; AZATHIOPRINE; BELATACEPT; CALCINEURIN INHIBITOR; CALCIUM CHANNEL BLOCKING AGENT; COMPLEMENT COMPONENT C4D; CORTICOSTEROID; CYCLOSPORIN A; CYTOCHROME P450 3A5; DACLIZUMAB; MACROLIDE; MULTIDRUG RESISTANCE PROTEIN 1; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RAPAMYCIN; TACROLIMUS;

ACUTE GRAFT REJECTION; ALLOIMMUNITY; ANTIBODY MEDIATED REJECTION; AREA UNDER THE CURVE; ARTERIOSCLEROSIS; DIARRHEA; DIURESIS; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG METABOLISM; DRUG SAFETY; ETHNICITY; FOOD INTAKE; GENETIC POLYMORPHISM; GLOMERULOSCLEROSIS; GRAFT DYSFUNCTION; GRAFT FAILURE; GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; HYALINE DEGENERATION; IMMUNE COMPLEX NEPHRITIS; IMMUNOSUPPRESSIVE TREATMENT; INTERSTITIAL NEPHRITIS; INTESTINE ABSORPTION; KIDNEY ALLOGRAFT; KIDNEY DYSFUNCTION; KIDNEY FIBROSIS; KIDNEY INJURY; KIDNEY PANCREAS TRANSPLANTATION; KIDNEY TRANSPLANTATION; KIDNEY TUBULE DAMAGE; KIDNEY VASCULAR RESISTANCE; LIVER TRANSPLANTATION; LOW DRUG DOSE; NEPHROTOXICITY; NONHUMAN; ORGAN TRANSPLANTATION; OUTCOME ASSESSMENT; PANCREAS TRANSPLANTATION; PHARMACOGENETICS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR;

EID: 84879164277     PISSN: 02508095     EISSN: 14219670     Source Type: Journal    
DOI: 10.1159/000351648     Document Type: Review

References (97)

1. Lamb KE, Lodhi S, Meier-Kriesche HU: Long-term renal allograft survival in the United States: a critical reappraisal. Am J Transplant 2011; 11: 450-462.
2. Nankivell BJ, Borrows RJ, Fung CL, O'Connell PJ, Allen RD, Chapman JR: The natural history of chronic allograft nephropathy. N Engl J Med 2003; 349: 2326-2333.
3. Takahashi N, Hayano T, Suzuki M: Peptidylprolyl cis-trans isomerase is the cyclosporin A-binding protein cyclophilin. Nature 1989; 337: 473-475.
4. Harding MW, Galat A, Uehling DE, Schreiber SL: A receptor for the immunosuppressant FK506 is a cis-trans peptidyl-prolyl isomerase. Nature 1989; 341: 758-760.
5. Fischer G, Wittmann-Liebold B, Lang K, Kiefhaber T, Schmid FX: Cyclophilin and peptidyl-prolyl cis-trans isomerase are probably identical proteins. Nature 1989; 337: 476-478.
6. Jain J, McCaffrey PG, Miner Z, Kerppola TK, Lambert JN, Verdine GL, et al: The T-cell transcription factor NFATp is a substrate for calcineurin and interacts with Fos and Jun. Nature 1993; 365: 352-355.
7. Flanagan WM, Corthesy B, Bram RJ, Crabtree GR: Nuclear association of a T-cell transcription factor blocked by FK-506 and cyclosporin A. Nature 1991; 352: 803-807.
8. Macian F: NFAT proteins: key regulators of T-cell development and function. Nat Rev Immunol 2005; 5: 472-484.
9. Clipstone NA, Crabtree GR: Identification of calcineurin as a key signalling enzyme in Tlymphocyte activation. Nature 1992; 357: 695-697.
10. O'Keefe SJ, Tamura J, Kincaid RL, Tocci MJ, O'Neill EA: FK-506-And CsA-sensitive activation of the interleukin-2 promoter by calcineurin. Nature 1992; 357: 692-694.
11. Kung L, Batiuk TD, Palomo-Pinon S, Noujaim J, Helms LM, Halloran PF: Tissue distribution of calcineurin and its sensitivity to inhibition by cyclosporine. Am J Transplant 2001; 1: 325-333.
12. Halloran PF, Helms LM, Kung L, Noujaim J: The temporal profile of calcineurin inhibition by cyclosporine in vivo. Transplantation 1999; 68: 1356-1361.
13. Sollinger HW: Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group. Transplantation 1995; 60: 225-232.
14. English J, Evan A, Houghton DC, Bennett WM: Cyclosporine-induced acute renal dysfunction in the rat. Evidence of arteriolar vasoconstriction with preservation of tubular function. Transplantation 1987; 44: 135-141.
15. Laskow DA, Curtis JJ, Luke RG, Julian BA, Jones P, Deierhoi MH, et al: Cyclosporine-induced changes in glomerular filtration rate and urea excretion. Am J Med 1990; 88: 497-502.
16. Bobadilla NA, Gamba G: New insights into the pathophysiology of cyclosporine nephrotoxicity: a role of aldosterone. Am J Physiol Renal Physiol 2007; 293:F2-F9.
17. Burdmann EA, Andoh TF, Yu L, Bennett WM: Cyclosporine nephrotoxicity. Semin Nephrol 2003; 23: 465-476.
18. Kon V, Sugiura M, Inagami T, Harvie BR, Ichikawa I, Hoover RL: Role of endothelin in cyclosporine-induced glomerular dysfunction. Kidney Int 1990; 37: 1487-1491.
19. Textor SC, Burnett JC Jr., Romero JC, Canzanello VJ, Taler SJ, Wiesner R, et al: Urinary endothelin and renal vasoconstriction with cyclosporine or FK506 after liver transplantation. Kidney Int 1995; 47: 1426-1433.
20. Hocherl K, Dreher F, Vitzthum H, Kohler J, Kurtz A: Cyclosporine A suppresses cyclooxygenase-2 expression in the rat kidney. J Am Soc Nephrol 2002; 13: 2427-2436.
21. Hocherl K, Kees F, Kramer BK, Kurtz A: Cyclosporine A attenuates the natriuretic action of loop diuretics by inhibition of renal COX-2 expression. Kidney Int 2004; 65: 2071-2080.
22. Andoh TF, Bennett WM: Chronic cyclosporine nephrotoxicity. Curr Opin Nephrol Hypertens 1998; 7: 265-270.
23. Mihatsch MJ, Kyo M, Morozumi K, Yamaguchi Y, Nickeleit V, Ryffel B: The side-effects of ciclosporine-A and tacrolimus. Clin Nephrol 1998; 49: 356-363.
24. Kershner RP, Fitzsimmons WE: Relationship of FK506 whole blood concentrations and efficacy and toxicity after liver and kidney transplantation. Transplantation 1996; 62: 920-926.
25. Lemahieu W, Maes B, Verbeke K, Rutgeerts P, Geboes K, Vanrenterghem Y: Cytochrome P450 3A4 and P-glycoprotein activity and assimilation of tacrolimus in transplant patients with persistent diarrhea. Am J Transplant 2005; 5: 1383-1391.
26. International Neoral Renal Transplantation Study Group. Cyclosporine microemulsion (Neoral) absorption profiling and sparsesample predictors during the first 3 months after renal transplantation. Am J Transplant 2002; 2: 148-156.
27. Knight SR, Morris PJ: The clinical benefits of cyclosporine C2-level monitoring: a systematic review. Transplantation 2007; 83: 1525-1535.
28. Nankivell BJ, Borrows RJ, Fung CL, O'Connell PJ, Chapman JR, Allen RD: Calcineurin inhibitor nephrotoxicity: longitudinal assessment by protocol histology. Transplantation 2004; 78: 557-565.
29. Naesens M, Lerut E, Damme BV, Vanrenterghem Y, Kuypers DR: Tacrolimus exposure and evolution of renal allograft histology in the first year after transplantation. Am J Transplant 2007; 7: 2114-2123.
30. Seron D, Moreso F, Fulladosa X, Hueso M, Carrera M, Grinyo JM: Reliability of chronic allograft nephropathy diagnosis in sequential protocol biopsies. Kidney Int 2002; 61: 727-733.
31. Ekberg H, Bernasconi C, Noldeke J, Yussim A, Mjornstedt L, Erken U, et al: Cyclosporine, tacrolimus and sirolimus retain their distinct toxicity profiles despite low doses in the Symphony study. Nephrol Dial Transplant 2010; 25: 2004-2010.
32. Shihab FS, Waid TH, Conti DJ, Yang H, Holman MJ, Mulloy LC, et al: Conversion from cyclosporine to tacrolimus in patients at risk for chronic renal allograft failure: 60-month results of the CRAF Study. Transplantation 2008; 85: 1261-1269.
33. Ekberg H, Grinyo J, Nashan B, Vanrenterghem Y, Vincenti F, Voulgari A, et al: Cyclosporine sparing with mycophenolate mofetil, daclizumab and corticosteroids in renal allograft recipients: the CAESAR Study. Am J Transplant 2007; 7: 560-570.
34. Hesselink DA, Bouamar R, van Gelder T: The pharmacogenetics of calcineurin inhibitorrelated nephrotoxicity. Ther Drug Monit 2010; 32: 387-393.
35. Naesens M, Lerut E, de Jonge H, Van Damme B, Vanrenterghem Y, Kuypers DR: Donor age and renal P-glycoprotein expression associate with chronic histological damage in renal allografts. J Am Soc Nephrol 2009; 20: 2468-2480.
36. Joy MS, Hogan SL, Thompson BD, Finn WF, Nickeleit V: Cytochrome P450 3A5 expression in the kidneys of patients with calcineurin inhibitor nephrotoxicity. Nephrol Dial Transplant 2007; 22: 1963-1968.
37. Bandur S, Petrasek J, Hribova P, Novotna E, Brabcova I, Viklicky O: Haplotypic structure of ABCB1/MDR1 gene modifies the risk of the acute allograft rejection in renal transplant recipients. Transplantation 2008; 86: 1206-1213.
38. Quteineh L, Verstuyft C, Furlan V, Durrbach A, Letierce A, Ferlicot S, et al: Influence of CYP3A5 genetic polymorphism on tacrolimus daily dose requirements and acute rejection in renal graft recipients. Basic Clin Pharmacol Toxicol 2008; 103: 546-552.
39. Naesens M, Kuypers DR, Sarwal M: Calcineurin inhibitor nephrotoxicity. Clin J Am Soc Nephrol 2009; 4: 481-508.
40. Djamali A, Reese S, Hafez O, Vidyasagar A, Jacobson L, Swain W, et al: Nox2 is a mediator of chronic CsA nephrotoxicity. Am J Transplant 2012; 12: 1997-2007.
41. Elzinga LW, Rosen S, Burdmann EA, Hatton DC, Lindsley J, Bennett WM: The role of renal sympathetic nerves in experimental chronic cyclosporine nephropathy. Transplantation 2000; 69: 2149-153.
42. Hausberg M, Lang D, Levers A, Suwelack B, Kisters K, Tokmak F, et al: Sympathetic nerve activity in renal transplant patients before and after withdrawal of cyclosporine. J Hypertens 2006; 24: 957-964.
43. Myers BD, Ross J, Newton L, Luetscher J, Perlroth M: Cyclosporine-Associated chronic nephropathy. N Engl J Med 1984; 311: 699-705.
44. Ojo AO, Held PJ, Port FK, Wolfe RA, Leichtman AB, Young EW, et al: Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med 2003; 349: 931-940.
45. Soin AS, Rasmussen A, Jamieson NV, Watson CJ, Friend PJ, Wight DG, et al: CsA levels in the early posttransplant period-predictive of chronic rejection in liver transplantation? Transplantation 1995; 59: 1119-1123.
46. Yoshida EM, Marotta PJ, Greig PD, Kneteman NM, Marleau D, Cantarovich M, et al: Evaluation of renal function in liver transplant recipients receiving daclizumab (Zenapax), mycophenolate mofetil, and a delayed, low-dose tacrolimus regimen vs. a standarddose tacrolimus and mycophenolate mofetil regimen: a multicenter randomized clinical trial. Liver Transpl 2005; 11: 1064-1072.
47. McGuire BM, Julian BA, Bynon JS Jr., Cook WJ, King SJ, Curtis JJ, et al: Brief communication: glomerulonephritis in patients with hepatitis C cirrhosis undergoing liver transplantation. Ann Intern Med 2006; 144: 735-741.
48. Bloom RD, Reese PP: Chronic kidney disease after nonrenal solid-organ transplantation. J Am Soc Nephrol 2007; 18: 3031-3041.
49. Canales M, Youssef P, Spong R, Ishani A, Savik K, Hertz M, et al: Predictors of chronic kidney disease in long-term survivors of lung and heart-lung transplantation. Am J Transplant 2006; 6: 2157-2163.
50. Hamour IM, Omar F, Lyster HS, Palmer A, Banner NR: Chronic kidney disease after heart transplantation. Nephrol Dial Transplant 2009; 24: 1655-1662.
51. O'Riordan A, Dutt N, Cairns H, Rela M, O'Grady JG, Heaton N, et al: Renal biopsy in liver transplant recipients. Nephrol Dial Transplant 2009; 24: 2276-2282.
52. Kim JY, Akalin E, Dikman S, Gagliardi R, Schiano T, Bromberg J, et al: The variable pathology of kidney disease after liver transplantation. Transplantation 2010; 89: 215-221.
53. Young EW, Ellis CN, Messana JM, Johnson KJ, Leichtman AB, Mihatsch MJ, et al: A prospective study of renal structure and function in psoriasis patients treated with cyclosporin. Kidney Int 1994; 46: 1216-1222.
54. Isnard Bagnis C, Tezenas du Montcel S, Beaufils H, Jouanneau C, Jaudon MC, Maksud P, et al: Long-term renal effects of low-dose cyclosporine in uveitis-treated patients: follow-up study. J Am Soc Nephrol 2002; 13: 2962-2968.
55. Pei Y, Scholey JW, Katz A, Schachter R, Murphy GF, Cattran D: Chronic nephrotoxicity in psoriatic patients treated with low-dose cyclosporine. Am J Kidney Dis 1994; 23: 528-536.
56. Mihatsch MJ, Thiel G, Basler V, Ryffel B, Landmann J, von Overbeck J, et al: Morphological patterns in cyclosporine-treated renal transplant recipients. Transplant Proc 1985; 17: 101-116.
57. Nankivell BJ, Wavamunno MD, Borrows RJ, Vitalone M, Fung CL, Allen RD, et al: Mycophenolate mofetil is associated with altered expression of chronic renal transplant histology. Am J Transplant 2007; 7: 366-376.
58. Mazur MJ, Rea DJ, Griffin MD, Larson TS, Prieto M, Gloor JM, et al: Decline in native renal function early after bladder-drained pancreas transplantation alone. Transplantation 2004; 77: 844-849.
59. Snanoudj R, Royal V, Elie C, Rabant M, Girardin C, Morelon E, et al: Specificity of histological markers of long-term CNI nephrotoxicity in kidney-transplant recipients under low-dose cyclosporine therapy. Am J Transplant 2011; 11: 2635-2646.
60. Mengel M, Mihatsch M, Halloran PF: Histological characteristics of calcineurin inhibitor toxicity-there is no such thing as specificity! Am J Transplant 2011; 11: 2549-2550.
61. Nankivell BJ, Chapman JR: Chronic allograft nephropathy: current concepts and future directions. Transplantation 2006; 81: 643-654.
62. Randhawa P, Ho A, Shapiro R, Vats A, Swalsky P, Finkelstein S, et al: Correlates of quantitative measurement of BK polyomavirus (BKV) DNA with clinical course of BKV infection in renal transplant patients. J Clin Microbiol 2004; 42: 1176-1180.
63. Buehrig CK, Lager DJ, Stegall MD, Kreps MA, Kremers WK, Gloor JM, et al: Influence of surveillance renal allograft biopsy on diagnosis and prognosis of polyomavirus-Associated nephropathy. Kidney Int 2003; 64: 665-673.
64. Hirsch HH: Polyomavirus BK nephropathy: a (re-)emerging complication in renal transplantation. Am J Transplant 2002; 2: 25-30.
65. Kahan BD: Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study. The Rapamune US Study Group. Lancet 2000; 356: 194-202.
66. Halloran PF: Sirolimus and cyclosporin for renal transplantation. Lancet 2000; 356: 179-180.
67. Andoh TF, Lindsley J, Franceschini N, Bennett WM: Synergistic effects of cyclosporine and rapamycin in a chronic nephrotoxicity model. Transplantation 1996; 62: 311-316.
68. Ciancio G, Burke GW, Gaynor JJ, Ruiz P, Roth D, Kupin W, et al: A randomized long-term trial of tacrolimus/sirolimus versus tacrolimus/mycophenolate versus cyclosporine/sirolimus in renal transplantation: three-year analysis. Transplantation 2006; 81: 845-852.
69. Meier-Kriesche HU, Schold JD, Srinivas TR, Howard RJ, Fujita S, Kaplan B: Sirolimus in combination with tacrolimus is associated with worse renal allograft survival compared to mycophenolate mofetil combined with tacrolimus. Am J Transplant 2005; 5: 2273-2280.
70. Mendez R, Gonwa T, Yang HC, Weinstein S, Jensik S, Steinberg S, et al: A prospective, randomized trial of tacrolimus in combination with sirolimus or mycophenolate mofetil in kidney transplantation: results at 1 year. Transplantation 2005; 80: 303-309.
71. Ekberg H, Tedesco-Silva H, Demirbas A, Vitko S, Nashan B, Gurkan A, et al: Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med 2007; 357: 2562-2575.
72. Larson TS, Dean PG, Stegall MD, Griffin MD, Textor SC, Schwab TR, et al: Complete avoidance of calcineurin inhibitors in renal transplantation: a randomized trial comparing sirolimus and tacrolimus. Am J Transplant 2006; 6: 514-522.
73. Dean PG, Grande JP, Sethi S, Park WD, Griffin MD, Cosio FG, et al: Kidney transplant histology after one year of continuous therapy with sirolimus compared with tacrolimus. Transplantation 2008; 85: 1212-1215.
74. Flechner SM, Glyda M, Cockfield S, Grinyo J, Legendre C, Russ G, et al: The ORION study: comparison of two sirolimus-based regimens versus tacrolimus and mycophenolate mofetil in renal allograft recipients. Am J Transplant 2011; 11: 1633-1644.
75. Srinivas TR, Schold JD, Guerra G, Eagan A, Bucci CM, Meier-Kriesche HU: Mycophenolate mofetil/sirolimus compared to other common immunosuppressive regimens in kidney transplantation. Am J Transplant 2007; 7: 586-594.
76. Heilman RL, Cortese C, Geiger XJ, Younan K, Wadei HM, Mai ML, et al: Impact of early conversion from tacrolimus to sirolimus on chronic allograft changes in kidney recipients on rapid steroid withdrawal. Transplantation 2012; 93: 47-53.
77. Vincenti F, Charpentier B, Vanrenterghem Y, Rostaing L, Bresnahan B, Darji P, et al: A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study). Am J Transplant 2010; 10: 535-546.
78. Durrbach A, Pestana JM, Pearson T, Vincenti F, Garcia VD, Campistol J, et al: A phase III study of belatacept versus cyclosporine in kidney transplants from extended criteria donors (BENEFIT-EXT study). Am J Transplant 2010; 10: 547-557.
79. Lebranchu Y, Thierry A, Toupance O, Westeel PF, Etienne I, Thervet E, et al: Efficacy on renal function of early conversion from cyclosporine to sirolimus months after renal transplantation: CONCEPT study. Am J Transplant 2009; 9: 1115-1123.
80. Weir MR, Mulgaonkar S, Chan L, Shidban H, Waid TH, Preston D, et al: Mycophenolate mofetil-based immunosuppression with sirolimus in renal transplantation: a randomized, controlled Spare-the-Nephron trial. Kidney Int 2011; 79: 897-907.
81. Schena FP, Pascoe MD, Alberu J, del Carmen Rial M, Oberbauer R, Brennan DC, et al: Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial. Transplantation 2009; 87: 233-242.
82. Lebranchu Y, Thierry A, Thervet E, Buchler M, Etienne I, Westeel PF, et al: Efficacy and safety of early cyclosporine conversion to sirolimus with continued MMF-four-year results of the Postconcept study. Am J Transplant 2011; 11: 1665-1675.
83. Srinivas TR, Flechner SM, Poggio ED, Askar M, Goldfarb DA, Navaneethan SD, et al: Glomerular filtration rate slopes have significantly improved among renal transplants in the United States. Transplantation 2010; 90: 1499-1505.
84. Halloran PF, Wadgymar A, Ritchie S, Falk J, Solez K, Srinivasa NS: The significance of the anti-class I antibody response. I. Clinical and pathologic features of anti-class I-mediated rejection. Transplantation 1990; 49: 85-91.
85. Iványi B, Fahmy H, Brown H, Szenohradszky P, Halloran PF, Solez K: Peritubular capillaries in chronic renal allograft rejection: a quantitative ultrastructural study. Hum Pathol 2000; 31: 1129-1138.
86. Mao Q, Terasaki PI, Cai J, Briley K, Catrou P, Haisch C, et al: Extremely high association between appearance of HLA antibodies and failure of kidney grafts in a five-year longitudinal study. Am J Transplant 2007; 7: 864-871.
87. Racusen LC, Halloran PF, Solez K: Banff 2003 meeting report: new diagnostic insights and standards. Am J Transplant 2004; 4: 1562-1566.
88. Issa N, Cosio FG, Gloor JM, Sethi S, Dean PG, Moore SB, et al: Transplant glomerulopathy: risk and prognosis related to anti-human leukocyte antigen class II antibody levels. Transplantation 2008; 86: 681-685.
89. Sis B, Campbell PM, Mueller T, Hunter C, Cockfield SM, Cruz J, et al: Transplant glomerulopathy, late antibody-mediated rejection and the ABCD tetrad in kidney allograft biopsies for cause. Am J Transplant 2007; 7: 1743-1752.
90. Solez K, Colvin RB, Racusen LC, Haas M, Sis B, Mengel M, et al: Banff classification of renal allograft pathology: updates and future directions. Am J Transplant 2008; 8: 753-760.
91. Gaston RS, Cecka JM, Kasiske BL, Fieberg AM, Leduc R, Cosio FC, et al: Evidence for antibody-mediated injury as a major determinant of late kidney allograft failure. Transplantation 2010; 90: 68-74.
92. Einecke G, Sis B, Reeve J, Mengel M, Campbell PM, Hidalgo LG, et al: Antibody-mediated microcirculation injury is the major cause of late kidney transplant failure. Am J Transplant 2009; 9: 2520-2531.
93. El-Zoghby ZM, Stegall MD, Lager DJ, Kremers WK, Amer H, Gloor JM, et al: Identifying specific causes of kidney allograft loss. Am J Transplant 2009; 9: 527-535.
94. Hill GS, Nochy D, Bruneval P, Duong van Huyen JP, Glotz D, Suberbielle C, et al: Donor-specific antibodies accelerate arteriosclerosis after kidney transplantation. J Am Soc Nephrol 2011; 22: 975-983.
95. Stegall MD, Park WD, Larson TS, Gloor JM, Cornell LD, Sethi S et al. The histology of solitary renal allografts at 1 and 5 years after transplantation. Am J Transplant 2011; 11: 698-707.
96. Sellarés J, de Freitas DG, Mengel M, Reeve J, Einecke G, Sis B, et al: Understanding the causes of kidney transplant failure: the dominant role of antibody-mediated rejection and nonadherence. Am J Transplant 2012; 12: 388-399.
97. Famulski KS, Reeve J, de Freitas DG, Kreepala C, Chang J, Halloran PF: Kidney transplants with progressing chronic diseases express high levels of acute kidney injury transcripts. Am J Transplant 2013; 13: 634-644.